Biogen’s Drug for Alzheimer’s Could Cost Millions of Dollars

As per the trusted sources of information, the new Drug introduced by Biogen, named as Adulelm are pricy and they are likely to cost Medicare about billions of dollars in a year, as stated by the nonprofit organization named Kaiser Family Foundation on Thursday.

The US FDA had approved of the Drug earlier this week. It is the first Drug approved by the FDA for slow cognitive decline for the people suffering from Alzheimer’s diseases. It is the first new medicine for the illness over last two decades.

The company stated that the cost of the Drug would be approximately USD 55,000 for an annual course of the new treatment, which is higher by some USD 10,000 to USD 25,000 cost, as expected by the analysts at Wall Street.This is the wholesale price of the medicine. The cost at which it will be sold to the patient will depend on the health coverage of the patient in need of these Drug.As per the statistics, the Alzheimer’s disease is known to affect about over 6 million individuals in the United States.The disease majorly affects the people who are aged 65 and older.

Biogen states that their Drug is likely to be covered about almost 80% of the people who are suffering from Alzheimer’s, with the help of the federal health insurance program for the elderly.The company is yet to disclose about how the medical beneficiaries will handle the Drug. But even if we make a small estimate, it would cost a huge amount to the company.